Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $17.6 million.

  • Fate Therapeutics' Accumulated Expenses fell 2548.35% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.6 million, marking a year-over-year decrease of 2548.35%. This contributed to the annual value of $21.3 million for FY2024, which is 2241.04% down from last year.
  • According to the latest figures from Q3 2025, Fate Therapeutics' Accumulated Expenses is $17.6 million, which was down 2548.35% from $18.2 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Accumulated Expenses peaked at $54.0 million during Q3 2021, and registered a low of $17.2 million during Q1 2025.
  • Its 5-year average for Accumulated Expenses is $31.2 million, with a median of $28.5 million in 2023.
  • In the last 5 years, Fate Therapeutics' Accumulated Expenses soared by 26532.95% in 2021 and then tumbled by 4898.39% in 2023.
  • Over the past 5 years, Fate Therapeutics' Accumulated Expenses (Quarter) stood at $42.4 million in 2021, then rose by 27.16% to $53.9 million in 2022, then tumbled by 48.98% to $27.5 million in 2023, then fell by 22.41% to $21.3 million in 2024, then decreased by 17.69% to $17.6 million in 2025.
  • Its Accumulated Expenses was $17.6 million in Q3 2025, compared to $18.2 million in Q2 2025 and $17.2 million in Q1 2025.